Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567674 | 0.91 | SLC6A9 (0.76) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6566437 | 0.89 | SLC6A9 (0.70) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6568970 | 0.89 | SLC6A9 (0.66) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6567659 | 0.88 | SLC6A9 (0.67) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6566255 | 0.87 | SLC6A9 (0.75) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6565529 | 0.87 | SLC6A9 (0.83) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6826352 | 0.87 | SLC6A9 (0.62) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6826157 | 0.87 | SLC6A9 (0.78) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6564309 | 0.87 | SLC6A9 (0.65) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6565545 | 0.86 | SLC6A9 (0.76) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784299-B2 | CARBOCYCLIC ETHERS SUCH AS (METHYL-(3-(4-PHENOXY-PHENOXY)-3-PHENYL-PROPYL)-AMINO)-ACETIC ACID, USED AS NEUROTRANSMITTER ANTAGONISTS, FOR PROPHYLAXIS OF PSYCHOLOGICAL DISORDERS | PFIZER INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1406861-A1 | SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT | Pfizer Products Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030208081-A1 | Substituted aromatic ethers as inhibitors of glycine transport | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| US-6566550-B2 | Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders | PFIZER INC | 2003-05-20 | — | — | US | disclosed |
| US-20030013887-A1 | Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders | PFIZER INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2003000646-A1 | SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013887-A1 | Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders | SLC1A2, SLC1A1, SLC1A3 | SLC6A9 15/4885ALDH1A1 1330/4885CYP2D6 1027/4885 |
| US-20030208081-A1 | Substituted aromatic ethers as inhibitors of glycine transport | SLC1A2, SLC1A1, SLC6A1 | SLC6A9 10/4885ALDH1A1 2156/4885CYP2D6 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.